Affinia Therapeutics is a technology company.
Affinia Therapeutics has raised $210.0M across 3 funding rounds.
Affinia Therapeutics has raised $210.0M in total across 3 funding rounds.
Affinia Therapeutics is a biotech company developing transformative adeno-associated virus (AAV) gene therapies for devastating rare and prevalent diseases, particularly genetic cardiomyopathies and central nervous system (CNS) disorders.[1][2][3][4] It serves patients with high unmet needs by engineering novel AAV capsids for targeted delivery, solving key challenges in gene therapy like tissue specificity, safety, and efficacy to enable one-time treatments that correct defective genes.[2][4] The company's lead candidate, AFTX-201, targets BAG3-associated dilated cardiomyopathy and is advancing into Phase 1/2 trials with data expected in 2026, reflecting strong growth momentum backed by investors like F-Prime Capital since 2019.[1][2]
Affinia Therapeutics emerged in 2019 as a pioneering gene therapy company, founded to tackle longstanding delivery challenges in AAV-based therapies using rational design and AI-driven structural modeling.[1][4][5] Key backers include F-Prime Capital, with investment team members Robert Weisskoff, PhD, and Raj Basak, PhD, highlighting early traction from a strong life sciences syndicate.[1][3] Headquartered in Waltham, Massachusetts, the company quickly gained momentum by focusing on high-need areas like heart and CNS diseases, leveraging its proprietary ART (Affinia Rationally-designed Therapies) platform to engineer capsids with specific tissue tropisms.[2][4] This origin reflects a pivotal shift toward precision-engineered gene therapies amid growing demand for effective one-time treatments.[5]
Affinia stands out in gene therapy through these key strengths:
Affinia rides the gene therapy revolution, fueled by advances in AAV engineering and AI to overcome historical barriers like poor tissue targeting and immunogenicity, making therapies viable for larger patient populations.[2][4][5] Timing is ideal amid surging demand for curative treatments in cardiology and neurology, where traditional drugs fall short, and market forces like regulatory nods for AAV platforms (e.g., recent approvals) accelerate adoption.[1][2] By influencing the ecosystem through novel capsid tech, Affinia enables broader access to genetic medicines, potentially reshaping biotech R&D toward rational design over trial-and-error approaches.[3][4]
Affinia is poised for inflection with AFTX-201 Phase 1/2 readouts in 2026, potentially validating its platform and unlocking CNS/heart programs amid AI-biotech convergence.[2][4] Trends like expanded AAV manufacturing and precision medicine will propel growth, evolving Affinia from platform innovator to multi-product leader transforming devastating diseases. This positions it centrally in gene therapy's next wave, delivering on its mission to expand what's possible.[1][3]
Affinia Therapeutics has raised $210.0M in total across 3 funding rounds.
Affinia Therapeutics's investors include Atlas Venture, F-Prime Capital Partners, Ed Mathers, New Enterprise Associates.
Affinia Therapeutics has raised $210.0M across 3 funding rounds. Most recently, it raised $40.0M Series C in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $40.0M Series C | Atlas Venture, F-Prime Capital Partners, Ed Mathers, New Enterprise Associates | |
| May 1, 2021 | $110.0M Series B | Atlas Venture, F-Prime Capital Partners, Ed Mathers, New Enterprise Associates | |
| Mar 1, 2020 | $60.0M Series A | Atlas Venture, F-Prime Capital Partners, Ed Mathers, New Enterprise Associates |